XyloCor Raises $67.5 Million for Gene Therapy Trials

XyloCor Therapeutics, a clinical-stage biopharmaceutical company, has completed a $67.5 million Series B financing round, led by Jeito Capital with participation from EQT, Fountain Healthcare Partners, and Lumira Ventures. The funding aims to advance the clinical development of XC001, a novel gene therapy for cardiovascular diseases like refractory angina. The proceeds will support two double-blind Phase 2 clinical trials: one as a non-surgical endocardial treatment and another as an adjunctive therapy to coronary artery bypass graft surgery. With these steps, XyloCor aims to address significant unmet medical needs, potentially improving the quality of life for patients who have exhausted existing treatment options. With proven safety and efficacy from Phase 1/2 trials, XC001 represents a promising advance in gene therapy for cardiovascular conditions, aligning with Jeito Capital's mission to accelerate medical innovation.